Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Satellos Bioscience Inc

MSLE ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$10.01

▼ -1.72%

Market Cap $204.17M · Vol 4.63K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$204.17M

Micro Cap

Div Yield

N/A

EPS Growth

-18.90%

YoY

RSI (14)

56.08

Momentum

Beta

N/A

vs Market

52W High

$13.23

24.34% below

52W Low

$5.45

83.67% above

Volume

4.63K

Avg 10.08K

P/B

38.53

Price-to-book

ROE

N/A

Return on equity

Free Float

93.43%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Satellos Bioscience Inc (MSLE) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MSLE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.16%

+17.42%

+40.20%

-10.94%

YTD

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-24,873,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-59.76% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	38.53
P/FCF	N/A
EPS Growth	-18.90%
Outstanding Shares	20.84M

Technical Indicators

50-Day SMA	$8.58
200-Day SMA	$N/A
RSI (14)	56.08
Beta	N/A
52-Week High	$13.23
52-Week Low	$5.45

Volume Today	4.63K
Avg Daily Volume (30D)	10.08K
Relative Volume	0.46x
Volatility (10D)	29.03
Volatility (30D)	56.71
Free Float	93.43%

Analyst Consensus

BUY

Current Price $10.01

Mean Target $23.40

52W Low$5.45 52W High$13.23

Current

Target

$5.45 $13.23

Current Analyst target

+133.77% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SRK950

ISINCA80401L8033

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.39% ARGX.BR argenx SE +1.90% ARGX argenx SE +0.16% INSM Insmed Inc +0.55% 2269.HK WuXi Biologics (Cayman) Inc +2.74%

Company Profile

Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.